Vatansev Hulya, Yıldırım Mehmet Aykut, Kuccukturk Serkan, Karaselek Mehmet Ali, Kadiyoran Cengiz
Pulmonary Diseases Department, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
Department of General Surgery, Meram Medicine Faculty, Necmettin Erbakan University, Konya, Turkey.
Gastroenterol Res Pract. 2021 May 3;2021:5579795. doi: 10.1155/2021/5579795. eCollection 2021.
Coronavirus 2019 disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread to more than 200 countries worldwide. We aimed to present acute pancreatitis (AP) cases caused by SARS-CoV-2 viral infection.
The study was conducted retrospectively between April 2020 and June 2020 in Necmettin Erbakan University Meram, Medical Faculty Hospital, and 150 hospitalized patients diagnosed with COVID-19 were included. The degree of acute pancreatitis was determined according to the Atlanta classification. Organ failures of the patients were evaluated in terms of respiratory, cardiovascular, and nephrology according to the modified Marshall scoring (MMS) system, and CTSI (Balthazar score) and Imrie score were determined. Modified Marshall score ≥ 2 was considered organ failure.
A total of 29 patients were diagnosed with acute pancreatitis. All 29 patients with pancreatitis had respiratory failure during hospitalization. After the diagnosis of pancreatitis, there was no change in respiratory failure. According to the Atlanta classification, 19 patients had mild AP and 10 patients had moderate AP. Patients with acute pancreatitis were scored according to the CTSI (Balthazar score), and there were no patients with ≥6 severe pancreatitis. The CTSI score of 4 patients was 3. In addition, the Imrie score of the patients was determined and 8 patients with Imrie score ≥ 3 were identified.
The rate of pancreatic damage in SARS-CoV-2 infection was found to be 19% ( = 29) in our study. In our study, we highlight acute pancreatitis as a complication associated with COVID-19 and the importance of pancreatic evaluation in patients with COVID-19 and abdominal pain is demonstrated.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）已蔓延至全球200多个国家。我们旨在介绍由SARS-CoV-2病毒感染引起的急性胰腺炎（AP）病例。
该研究于2020年4月至2020年6月在内克梅丁·埃尔巴坎大学梅拉姆医学院附属医院进行回顾性研究，纳入150例确诊为COVID-19的住院患者。根据亚特兰大分类法确定急性胰腺炎的程度。根据改良马歇尔评分（MMS）系统对患者的器官功能衰竭进行呼吸、心血管和肾脏方面的评估，并确定CTSI（巴尔萨泽评分）和Imrie评分。改良马歇尔评分≥2被视为器官功能衰竭。
共有29例患者被诊断为急性胰腺炎。所有29例胰腺炎患者在住院期间均出现呼吸衰竭。胰腺炎诊断后，呼吸衰竭情况无变化。根据亚特兰大分类法，19例患者为轻度AP，10例患者为中度AP。对急性胰腺炎患者进行CTSI（巴尔萨泽评分）评分，无≥6分的重症胰腺炎患者。4例患者的CTSI评分为3分。此外，确定了患者的Imrie评分，发现8例患者的Imrie评分≥3分。
在我们的研究中，发现SARS-CoV-2感染中胰腺损伤的发生率为19%（n = 29）。在我们的研究中，我们强调急性胰腺炎是与COVID-19相关的一种并发症，并证明了对COVID-19且伴有腹痛患者进行胰腺评估的重要性。
